A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
Grommes C, Nandakumar S, Schaff LR, Gavrilovic I, Kaley TJ, Nolan CP, Stone J, Thomas AA, Tang SS, Wolfe J, Bozza A, Wongchai V, Hyde A, Barrett E, Lynch EA, Madzsar JT, Lin A, Piotrowski AF, Pentsova E, Francis JH, Hatzoglou V, Schultz N, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.
Grommes C, et al.
Clin Cancer Res. 2024 Sep 13;30(18):4005-4015. doi: 10.1158/1078-0432.CCR-24-0605.
Clin Cancer Res. 2024.
PMID: 38995739
Clinical Trial.